+2 more ↓
80%
Finnrick rating
#5 of 57 Semaglutide vendors
5 of 5 classifiable tests passed
natural 100% · customers 3.9★ (3)
methodology · Purity focus
Finnrick analysis · Semaglutide

HXNet Semaglutide's main caveats are early batch-ID gaps and one +22% overfill, not purity or identity misses. Recent labeled batches keep purity and fill within purity-focus limits, giving a low-concern but still prior-smoothed profile.

methodology →
vendor intelligence report
Vendor Intelligence Report: HXNet

Corporate records anchor HXNet to Hebei Xunou while the old domain is dead and sales have shifted into forum/Pastebin lanes. The report follows the HXTNT/KIRA/KARA reseller split, Janoshik chain-of-custody gaps, and documented refund/contamination disputes.

30 pages9 risk factors assessed2 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.04
90%
11
2
Tirzepatide
$0.35
89%
51
3
Retatrutide
$0.60
82%
46
4
Semaglutideselected
$1.00
80%
5
6
BPC-157
$0.60
69%
9
7
Cagrilintide
$1.76
63%
15
8
Tesamorelin
$1.80
50%
11
9
CJC-1295
-
49%
4
10
TB-500
$1.36
43%
5
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%1 Jan 2026: 70%18 Feb 2026: 73%28 Apr 2026: 76%2 Jun 2026: 78%12 Jun 2026: 81%9 Aug 2026: current 80%70%76%80%Jan 26Aug 26
Showing Semaglutide tests only
HXNet Semaglutide test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
12 Jun 2026Pass
Tested
lab nameView COA
2 Jun 2026Pass
Tested
lab nameView COA
28 Apr 2026Pass
Tested
lab nameView COA
18 Feb 2026Pass
Tested
lab nameView COA
1 Jan 2026Pass
Tested
lab nameView COA

About HXNet test results from Finnrick

HXNet is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 10 peptides and 162 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible HXNet peptides in this dataset are Tirzepatide (51 tests), Semaglutide (5 tests) and BPC-157 (9 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 162 recent tests.

Corrections
No corrections.